Elixia: A Revolution in Clinical Research
American Clinical Research Services, now known as Elixia, has rebranded to reflect its expanded clinical research and patient recruitment...
Jon Napitupulu
Samantree Medical Secures $14 Million to Revolutionize Surgical Care Globally
SamanTree Medical, a leading medical technology company specializing in surgical advancements, has secured $14 million in a Series B...
OPM Records Unprecedented Success in Phase 1 of OPM-101 Human Trials
Oncodesign Precision Medicine (OPM) has announced positive results from a Phase 1 trial evaluating OPM-101, a selective small molecule...
Dovato Surpasses Biktarvy in Largest HIV Clinical Trial
At the 25th International AIDS Conference in Munich, ViiV Healthcare will unveil significant findings from their portfolio of HIV...
Amylyx Acquires Avexitide for Treating Hyperinsulinemic Hypoglycemia
Amylyx Pharmaceuticals has acquired avexitide, an investigational therapy for hyperinsulinemic hypoglycemia, from Eiger BioPharmaceuticals. Avexitide, a novel GLP-1 receptor...
Ebglyss Receives NICE Recommendation for Moderate to Severe Atopic Dermatitis
The National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) as an additional treatment option for...
City of Hope and Mount Sinai Unlock New Treatment for Diabetes
Recent research published in Science Translational Medicine offers promising advancements in developing regenerative therapies for diabetes. A team of...
Pfizer: New Formulation of Oral GLP-1 Agonist Advances to Development Stage
Pfizer has selected a once-daily formulation of danuglipron, an oral GLP-1 receptor agonist, based on encouraging results from an...
Pluristyx and Humacyte Announce Partnership
Pluristyx, a renowned cellular therapy developer, has partnered with Humacyte, a biotechnology company specializing in bioengineered human tissue. This...
Obsidian’s OBX-115 T-Cell Therapy For Melanoma Receives FDA Fast Track
Obsidian Therapeutics has secured Fast Track Designation from the FDA for OBX-115, an engineered T-cell therapy targeting metastatic or...